Skip to main content

Vironova leads a new Influenza drug development program with EU funding of 6M Euros

Press Release   •   Feb 22, 2011 07:59 CET

STOCKHOLM – 22 february, 2011 – Vironova today announces Grant funding of 6MEuros to support influenza drug development.

Vironova is pleased to announce the successful completion of negotiations with the European Commission to co-finance an influenza drug development programme. The “FLUCURE” project received the highest ranking of the funding bid that was submitted to the European Commission´s Seventh Framework programme in competition with proposals from influenza scientists and companies around Europe.

The project, which is headed by Vironova, is a collaboration between 9 top European industry and academic partners (in Stockholm, Uppsala, Zurich, Amsterdam, Sofia, Freiburg, Saarbrücken, Siena, Vilnius).

“This is a very exciting project” said Vironova´s CEO, Mohammed Homman. “Antiviral drug discovery and development is a key business area for our company, and the FLUCURE project is a welcome addition to Vironova´s drug development portfolio. This is a unique opportunity to work with some of Europe´s top scientists experts to develop new drug candidates in the fight against influenza virus infection”

Vironova is the coordinator of the project, which will run from 2010-2014.


For further information please contact: Mr Mohammed Homman, CEO or Dr Heather Marshall-Heyman, FLUCURE Coordinator. Tel: +46 (0)8- 702 67 90

About Vironova

Vironova is a privately held Swedish biotech company dedicated to the development of novel antiviral therapeutics and virus diagnostics products to combat and prevent the spread of viral diseases.

For more information about Vironova, please visit

Attached Files

PDF document

Comments (0)

Add comment


Agree With Privacy Policy